CERo Therapeutics Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $12.1K
- Price
- $0.01
- % Change (Daily % change from the live per-ticker quote feed.)
- -9.50%
- Volume
- 83.9K
About
CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. This company was founded in 2021 and is headquartered in South San Francisco, California.
Quick stats
Shares outstanding1.2M
Computed float993.1K
Float / shares82.4%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001870404
Websitehttps://www.cero.bio
AI Summary
AI-generated1/4
standardbullishclinical trial
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
CERo Therapeutics reported a clinical update from its Phase 1 CERTAIN-T trial for CER-1236, noting that six patients have now been treated with no dose-limiting toxicities observed.
Patient five, who had refractory acute myeloid leukemia, saw bone marrow blast counts drop from baseline to 7% by Day 42, enabling an allogeneic stem cell transplant on Day 71.
The company has initiated the third planned cohort, which will evaluate a higher dose of one billion cells per patient and expand to include myelodysplastic syndromes and myelofibrosis.
Red flags
- Preliminary data only; no definitive conclusions regarding safety or efficacy can be made at this stage
- Single-patient anecdote for transplant eligibility; not a formal response assessment